Methods of treating PAH with combinations of ralinepag and other agents
AssigneesArena Pharmaceuticals, Inc., Lucie H. Clapp
InventorsDominic P. Behan, John W. Adams, Lucie H. Clapp
Life of this patent
Estimating the term…
Abstract
The present disclosure encompasses combinations of ralinepag with a cGMP-elevating agent or prostanoid such as riociguat, treprostinil, or iloprost for treating PAH. The disclosed combination therapy provides for advantages such as improved efficacy, improved safety, reduced doses and/or frequency of ralinepag and/or riociguat, reduced doses and/or frequency of ralinepag and/or treprostinil, and reduced doses and/or frequency of ralinepag and/or iloprost. In some embodiments, the clinical effectiveness of a reduced dose combination is additive or synergistic compared to that provided by the corresponding ralinepag, riociguat, treprostinil, and/or iloprost monotherapies.
Claims32
A method of treating pulmonary arterial hypertension in a human, comprising administering to the human with pulmonary arterial hypertension a therapeutically effective amount of ralinepag, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in combination with a therapeutically effective amount of riociguat.
A method of treating pulmonary arterial hypertension in a human, comprising administering to the human with pulmonary arterial hypertension ralinepag in combination with riociguat, wherein:
- ralinepag is administered to the human once or twice daily;
- and riociguat is administered to the human once, twice or three times daily.
A method of treating pulmonary arterial hypertension in a human, comprising administering to the human with pulmonary arterial hypertension ralinepag in combination with a soluble guanylate cyclase (sGC) stimulator.
A method of treating a pulmonary disease in a human in need of treatment with a selective prostacyclin (IP) receptor agonist, comprising administering to the human in need thereof ralinepag in combination with a soluble guanylate cyclase (sGC) stimulator.
A method of delaying disease progression in a human and/or reducing a risk of hospitalization for a disease or condition in a human, comprising administering to the human in need thereof ralinepag in combination with a soluble guanylate cyclase (sGC) stimulator, wherein the disease or condition is a pulmonary disease.
A method of improving the treatment of pulmonary arterial hypertension in a human comprising administering ralinepag to the human with pulmonary arterial hypertension in combination with a soluble guanylate cyclase (sGC) stimulator, wherein improving the treatment of pulmonary arterial hypertension in the human comprises a numerical improvement in the six-minute walk test.
A method of treating pulmonary arterial hypertension in a human comprising administering ralinepag to the human with pulmonary arterial hypertension in combination with a soluble guanylate cyclase (sGC) stimulator, wherein the co-administration of the soluble guanylate cyclase (sGC) stimulator with ralinepag comprises a reduction in the optimized monotherapy dose of ralinepag in the human.
Dependencies are inferred from the claim text.